These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 33285578)

  • 21. Psychedelics and hypnosis: Commonalities and therapeutic implications.
    Lemercier CE; Terhune DB
    J Psychopharmacol; 2018 Jul; 32(7):732-740. PubMed ID: 29938563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
    Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ
    Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelics and neonihilism: connectedness in a meaningless world.
    Plesa P; Petranker R
    Front Psychol; 2023; 14():1125780. PubMed ID: 37621941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethical and legal issues in psychedelic harm reduction and integration therapy.
    Pilecki B; Luoma JB; Bathje GJ; Rhea J; Narloch VF
    Harm Reduct J; 2021 Apr; 18(1):40. PubMed ID: 33827588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychologists' and psychotherapists' knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics.
    Kucsera A; Suppes T; Haug NA
    Clin Psychol Psychother; 2023; 30(6):1369-1379. PubMed ID: 37394242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
    Gorman I; Nielson EM; Molinar A; Cassidy K; Sabbagh J
    Front Psychol; 2021; 12():645246. PubMed ID: 33796055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why MDMA therapy for alcohol use disorder? And why now?
    Sessa B
    Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelic-assisted therapies: The past, and the need to move forward responsibly.
    Gardner J; Carter A; O'Brien K; Seear K
    Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing the Future of Psychedelics for Mental Health.
    Allen S
    IEEE Pulse; 2021; 12(4):6-10. PubMed ID: 34375272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. With great power comes great vulnerability: an ethical analysis of psychedelics' therapeutic mechanisms proposed by the REBUS hypothesis.
    Villiger D; Trachsel M
    J Med Ethics; 2023 Nov; 49(12):826-832. PubMed ID: 37045591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
    Johansen L; Liknaitzky P; Nedeljkovic M; Mastin-Purcell L; Murray G
    Syst Rev; 2022 May; 11(1):85. PubMed ID: 35513876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
    Miceli McMillan R; Jordens C
    Med Health Care Philos; 2022 Jun; 25(2):225-237. PubMed ID: 35064398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.